HPE Managing CINV pocket guide 2019 | Page 41

References 1 Aapro M et al. The effect of guideline- consistent antiemetic therapy on chemotherapy- induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 2012;23(8):1986–92. 2 Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 2016;374:1356–67. 3 Grunberg SM. Incidence of chemotherapy- induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261–8. 4 Jordan K et al. Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. Support Care Cancer 2016;24(11):4617–25. 5 Herrstedt J et al. 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer 2017;25(1):277–88. 6 NCCN Clinical Practice Guidelines in Oncology. Antiemesis. 1.2019. 7 Bosjnak SM, Gralla RJ, Schwartzberg L. Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists. Support Care Cancer 2017;Jan 20:doi: 10.1007/s00520-017-3585-z. 8 Hesketh PJ et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2018;35(28): 3240–61. 9 Chasen M et al. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. Support Care Cancer 2017;25(1):85–92. 10 Molassiotis A et al. Anticipatory nausea, risk factors, and its impact on chemotherapy- induced nausea and vomiting: Results from the Pan European Emesis Registry Study. J Pain Symptom Manage 2016;51:987–93. 11 Lopes G et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥1%: Open-label, phase 3 KEYNOTE-042 study. J Clin Oncol 2018;38(suppl):abstr LBA4. 12 Schwartzberg LS. Chemotherapy- induced nausea and vomiting: clinician and patient perspectives. J Support Oncol 2007;5(supplement 1):5–12. 13 Curran MP et al. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 2009;69(13):1853–78. 14 Bloechl-Daum B et al. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472–8. 15 Haiderali A et al. Impact on daily functioning and indirect / direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population. Support Care Cancer 2011;19:843–51. 16 Carver C et al. Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. J Med Econ 2011;14:87–98. 17 Turini M et al. An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries. Drugs Context 2015;4:212285. 18 Jordan K et al. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): Content and implementation in daily routine practice. Eur J Pharmacol 2014;722:197–202. 19 Aapro M et al. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Support Care Cancer 2017;25(4):1127–35. 20 Gralla E. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14(10):1570–7 21 Eisenberg P. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Cancer 2003;98:2473–82 22 Aapro M et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy- induced nausea and vomiting following highly emetogenic chemotherapy. 2006 Ann Oncol 17;1441–9. 23 Saito M. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009;10:115–24. hospitalpharmacyeurope.com | 2019 | 41